Table 4.

Dominant SARS-CoV B Cell Epitope Regions

SARS-CoV		SARS-CoV-2
Sequence	Max RF	Sequence	Proteina	Mapped Start–End	Identity (%)
DAVDCSQNPLAELKCSVKSFEIDKGIYQTSNF	0.504	DAVDCALDPLSETKCTLKSFTVEKGIYQTSN	S	287–317	69
VCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVIT	0.745	VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVI	S	524–598	80
GTNASSEVAVLYQDVNCTDVSTAIHADQLTPAWRIYSTGNN	0.709	GTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGS	S	601–640	78
FSQILPDPLKPTKRSFIED	0.365	FSQILPDPSKPSKRSFIE	S	802–819	89
FGAGAALQIPFAMQMAYRFNGIG	0.367	FGAGAALQIPFAMQMAYRFNGI	S	888–909	100
MADNGTITVEELKQLLEQWNLVIG	0.460	MADSNGTITVEELKKLLEQWNLVI	M	1–24	92
PLMESELVIGAVIIRGHLRMA	0.457	PLLESELVIGAVILRGHLRI	M	132–151	90
PQGLPNNTASWFTALTQHGKEE	0.537	RPQGLPNNTASWFTALTQHGK	N	42–62	95
NNAATVLQLPQGTTLPKGFYA	0.543	NNNAATVLQLPQGTTLPKGF	N	153–172	95
KHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADMDD	0.82	NKHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADM	N	355–401	90

S, surface glycoprotein; M, membrane protein; N, nucleocapsid phosphoprotein